India to United States: Escitalopram Export Trade Route
India has recorded 696 verified shipments of Escitalopram exported to United States, representing a combined trade value of $41.1M USD. This corridor is served by 12 active Indian exporters, with an average shipment value of $59.0K USD. The leading Indian exporter is AUROBINDO PHARMA LTD, which accounts for 27% of total export value with 146 shipments worth $10.9M USD. On the buying side, TORRENT PHARMA INC is the largest importer in United States with $9.0M USD in purchases. The top 3 suppliers — AUROBINDO PHARMA LTD, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LIMITED — together control 71% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Escitalopram corridor is one of India's established pharmaceutical export routes, with 696 shipments documented worth a combined $41.1M USD. The route is dominated by AUROBINDO PHARMA LTD, which alone accounts for roughly 27% of all export value, reflecting the consolidated nature of India's escitalopram manufacturing sector.
Across 12 active suppliers, the average shipment value stands at $59.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 71% of all shipments, consistent with escitalopram's non-urgent bulk-order profile.
Shipment activity peaks during October–December, with an average transit time of 31 days port-to-port. The route has recorded an annual growth rate of 25.7%, placing it at rank #15 among India's top escitalopram export destinations globally.
On the import side, key buyers of Indian escitalopram in United States include TORRENT PHARMA INC, AUROLOGISTICS LLC (AUROBINDO PHARMA, AUROLOGISTICS LLC AUROBINDO PHARM and 40 others. TORRENT PHARMA INC is the single largest importer with 64 shipments valued at $9.0M USD.
Route Characteristics
- Average transit31 days
- Peak seasonQ4
- Primary modeSea freight
- Top portHYDERABAD ICD
Market Position
- Global rank#15
- Annual growth+25.7%
- Demand growth+21.6%
- Regulatory ease72/100
Top 10 Indian Escitalopram Exporters to United States
Showing top 10 of 12 Indian suppliers exporting Escitalopram to United States, ranked by total trade value (USD)
| Rank | Supplier (Indian Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD Avg $74.6K per shipment | 146 | $10.9M | 26.5% |
| 2 | TORRENT PHARMACEUTICALS LTD Avg $143.0K per shipment | 68 | $9.7M | 23.7% |
| 3 | AUROBINDO PHARMA LIMITED Avg $103.1K per shipment | 84 | $8.7M | 21.1% |
| 4 | GRAVITI PHARMACEUTICALS PRIVATE LIMITED Avg $20.9K per shipment | 258 | $5.4M | 13.2% |
| 5 | TORRENT PHARMACEUTICALS LIMITED Avg $71.4K per shipment | 52 | $3.7M | 9.0% |
| 6 | CIPLA LIMITED Avg $69.8K per shipment | 18 | $1.3M | 3.1% |
| 7 | MACLEODS PHARMACEUTICALS LTD Avg $22.0K per shipment | 41 | $904.0K | 2.2% |
| 8 | HETERO LABS LIMITED Avg $18.1K per shipment | 13 | $235.3K | 0.6% |
| 9 | HETERO LABS LIMITED Avg $36.9K per shipment | 5 | $184.6K | 0.4% |
| 10 | MACLEODS PHARMACEUTICALS LIMITED Avg $21.5K per shipment | 5 | $107.7K | 0.3% |
This table shows the top 10 of 12 Indian companies exporting escitalopram to United States, ranked by total trade value. The listed exporters are: AUROBINDO PHARMA LTD, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LIMITED, GRAVITI PHARMACEUTICALS PRIVATE LIMITED, TORRENT PHARMACEUTICALS LIMITED, CIPLA LIMITED, MACLEODS PHARMACEUTICALS LTD, HETERO LABS LIMITED, HETERO LABS LIMITED, MACLEODS PHARMACEUTICALS LIMITED. AUROBINDO PHARMA LTD is the dominant supplier with 146 shipments worth $10.9M USD, giving it a 27% market share. The top 3 suppliers together account for 71% of the total trade value on this route.
Showing top 10 of 12 total Indian exporters on the India to United States Escitalopram export route.
Top 10 Escitalopram Importers in United States
Showing top 10 of 43 known buyers in United States receiving Escitalopram shipments from India, ranked by import value
On the receiving end of this trade route, the leading importers of Indian escitalopram in United States include TORRENT PHARMA INC, AUROLOGISTICS LLC (AUROBINDO PHARMA, AUROLOGISTICS LLC AUROBINDO PHARM, RISING PHARMA HOLDINGS, INC., AUROLOGISTICS LLC, among 43 total buyers. The largest importer is TORRENT PHARMA INC, accounting for $9.0M USD across 64 shipments — representing 22% of all escitalopram imports from India on this route.
| Rank | Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | TORRENT PHARMA INC | 64 | $9.0M | 21.8% |
| 2 | AUROLOGISTICS LLC (AUROBINDO PHARMA | 56 | $4.8M | 11.6% |
| 3 | AUROLOGISTICS LLC AUROBINDO PHARM | 28 | $3.5M | 8.5% |
| 4 | RISING PHARMA HOLDINGS, INC. | 174 | $3.1M | 7.6% |
| 5 | AUROLOGISTICS LLC | 32 | $2.9M | 7.0% |
| 6 | TORRENT PHARMA INC Importer EIN 36-4547412 | 26 | $2.3M | 5.6% |
| 7 | AUROLOGISTICS LLC, (AUROBINDO PHARM | 19 | $1.9M | 4.6% |
| 8 | RISING PHARMA HOLDINGS INC | 56 | $1.6M | 3.9% |
| 9 | XXRREXX PHXXMA XXC XXMPOXXER XXIN XX 45XX412X | 13 | $1.3M | 3.2% |
| 10 | AUROLOGISTICS LLC AUROBINDO PHARMA | 7 | $1.2M | 2.9% |
Showing top 10 of 43 Escitalopram importers in United States on this route.
Top 10 Escitalopram Formulations Imported by United States
Showing top 10 of 403 product formulations shipped on the India to United States Escitalopram route, ranked by trade value
United States imports a wide range of escitalopram formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — ESCITALOPRAM TABLETS USP 20MG — accounts for $2.1M USD across 24 shipments. There are 403 distinct product descriptions in the dataset, reflecting the variety of dosage forms and strengths imported.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | ESCITALOPRAM TABLETS USP 20MG | 24 | $2.1M | 5.2% |
| 2 | OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO. 13668-137-10) ( ESCITALOPRAM 20MG) NOS SIZE 1X1000 TABLETS | 9 | $1.8M | 4.5% |
| 3 | OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO. 13668-137-01) ( ESCITALOPRAM 20MG) NOS SIZE 1X1000 TABLETS | 6 | $1.4M | 3.4% |
| 4 | ESCITALOPRAM TABLETS USP 10 MG | 20 | $1.4M | 3.3% |
| 5 | ESCITALOPRAM TABLETS USP 10MG (ESCITALOPRAM TABLETS USP 10 MG) 500'S | 7 | $1.1M | 2.7% |
| 6 | ESCITALOPRAM 20 MG TABLETS (ESCITALOPRAMTABLETS USP 20 MG) 500'S | 8 | $1.1M | 2.7% |
| 7 | ESCITALOPRAM TABLETS USP 10MG | 10 | $811.5K | 2.0% |
| 8 | ESCITALOPRAM 20 MG TABLETS (ESCITALOPRAM | 5 | $643.1K | 1.6% |
| 9 | ESCITALOPRAM 20 MG TABLETS (ESCITALOPRAMTABLETS USP 20 MG) 100'S | 9 | $509.2K | 1.2% |
| 10 | OTHER - ESCITALOPRAM TABLETS USP 20MG (NDC NO.13668-137-10)( ESCITALOPRAM 20MG )NOS SIZE 1X1000 TABLETS | 4 | $503.0K | 1.2% |
Showing top 10 of 403 Escitalopram formulations imported by United States on this route.
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Sea freight dominates at 71%, typical for bulk pharmaceutical shipments.
Top Ports of Origin
HYDERABAD ICD handles the highest volume with 212 shipments. Transit time averages 31 days by sea.
Market Dynamics
India's escitalopram exports to United States are driven primarily by a handful of large-scale manufacturers. AUROBINDO PHARMA LTD with 146 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 12 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — AUROBINDO PHARMA LTD, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LIMITED — together account for 71% of total trade value on this route. The average shipment value of $59.0K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.
Beyond the primary product category, shipments on this route include closely related formulations such as other - escitalopram tablets usp 20mg (ndc no. 13668-137-10) ( escitalopram 20mg) nos size 1x1000 tablets and other - escitalopram tablets usp 20mg (ndc no. 13668-137-01) ( escitalopram 20mg) nos size 1x1000 tablets, suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.
On the buying side, TORRENT PHARMA INC is the largest importer with 64 shipments worth $9.0M USD — representing 22% of all escitalopram imports from India on this route. A total of 43 buyers are active on this corridor.
Route Statistics
- Trade Volume
- $41.1M
- Avg. Shipment
- $59.0K
- Suppliers
- 12
- Buyers
- 43
- Transit (Sea)
- ~31 days
- Annual Growth
- +25.7%
Related Analysis
Reverse Direction
United States → India — Escitalopram (Import)Other Escitalopram Routes
Unlock the Full India to United States Escitalopram Dataset
TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 696 shipments on this route.
Frequently Asked Questions — India to United States Escitalopram Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Indian companies export Escitalopram to United States?
The leading Indian exporters of Escitalopram to United States are AUROBINDO PHARMA LTD, TORRENT PHARMACEUTICALS LTD, AUROBINDO PHARMA LIMITED. AUROBINDO PHARMA LTD holds the largest market share at approximately 27% of total trade value on this route.
Q What is the total value of Escitalopram exports from India to United States?
India exports Escitalopram to United States worth approximately $41.1M USD across 696 recorded shipments. The average value per shipment is $59.0K USD.
Q Which ports does India use to ship Escitalopram to United States?
The most active port of origin is HYDERABAD ICD with 212 shipments. Indian exporters primarily use sea freight for this route, with 71% of shipments going by sea and 19% by air.
Q How long does shipping take from India to United States for Escitalopram?
The average transit time for Escitalopram shipments from India to United States is approximately 31 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during October–December.
Q Is the India to United States Escitalopram trade route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 25.7% with demand growth tracking at 21.6%. The route is ranked #15 among India's top Escitalopram export destinations globally.
Q How many suppliers are active on the India to United States Escitalopram route?
There are currently 12 active Indian suppliers exporting Escitalopram to United States. The market is moderately concentrated with AUROBINDO PHARMA LTD accounting for 27% of total shipment value.
Q Who are the main importers of Escitalopram from India in United States?
The leading importers of Indian Escitalopram in United States include TORRENT PHARMA INC, AUROLOGISTICS LLC (AUROBINDO PHARMA, AUROLOGISTICS LLC AUROBINDO PHARM, RISING PHARMA HOLDINGS, INC., AUROLOGISTICS LLC. TORRENT PHARMA INC is the largest buyer with 64 shipments worth $9.0M USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to United States export trade corridor identified from Indian Customs (DGFT) records for Escitalopram.
- 2.Supplier/Buyer Matching: 12 Indian exporters and 43 importers in United States matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 696 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
696 Verified Shipments
12 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists